domingo, 7 de octubre de 2012

National Guideline Clearinghouse | Organ-specific management and supportive care in chronic graft-versus-host disease.

full-text ►
National Guideline Clearinghouse | Organ-specific management and supportive care in chronic graft-versus-host disease.

Guideline Title

Organ-specific management and supportive care in chronic graft-versus-host disease.

Bibliographic Source(s)

Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, Shaw BE, on behalf of the Haemato-oncology Task Force of the British Committee [trunc]. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol 2012 Jul;158(1):62-78. [121 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

Br J Haematol. 2012 Jul;158(1):62-78. doi: 10.1111/j.1365-2141.2012.09131.x. Epub 2012 Apr 26.

Organ-specific management and supportive care in chronic graft-versus-host disease.

Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, Shaw BE; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation.

Source

Section of Haemato-oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Abstract

A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology and the British Society for Bone Marrow Transplantation has reviewed the available literature and made recommendations for the supportive care and management of organ-specific complications of chronic graft-versus-host disease (cGvHD). This guideline includes recommendations for the specific therapy of skin, oral, liver, gut, lung, ocular and genital manifestations of cGvHD and for the supportive care of these patients, including vaccinations and prophylaxis against infection. The goal of treatment should be effective control of GvHD while minimizing the risk of toxicity and relapse.
© 2012 Blackwell Publishing Ltd.